Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer

Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Soo Park, Ji, Youn, Jong-Chan, Shim, Chi Young, Hong, Geu-Ru, Lee, Choong-Kun, Kim, Jee Hyung, Park, Hyung Soon, Heo, Su Jin, Beom, Seung Hoon, Kim, Hyo Song, Rha, Sun Young, Chung, Hyun Cheol, Kang, Seok-Min, Jung, Minkyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617468/
https://www.ncbi.nlm.nih.gov/pubmed/28977908
http://dx.doi.org/10.18632/oncotarget.18700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617468/
https://www.ncbi.nlm.nih.gov/pubmed/28977908
http://dx.doi.org/10.18632/oncotarget.18700

Ejemplares similares